No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

CytoSMART Launches Its 1st Fluorescence Live-cell Imaging Microscope

Editor: What To Know

  • CytoSMART notes the device enables researchers to unravel cellular processes in real-time, while the cells are kept in a controlled environment inside a standard cell culture incubator.
  • By using automated imaging at regular time intervals, the temporal resolution of the fluorescent data is increased, leading to even more relevant data about the cellular processes.
  • Our customers have been asking us to develop a small and easy-to-use microscope with integrated image analysis of bright-field and fluorescence data.

November 3, 2020

CytoSMART Technologies today announced its first fluorescence live-cell imager. The CytoSMART Lux3 FL is a small live-cell imaging microscope equipped with one brightfield and two fluorescent channels (green and red).

CytoSMART notes the device enables researchers to unravel cellular processes in real-time, while the cells are kept in a controlled environment inside a standard cell culture incubator.

CytoSMART states their first fluorescence live-cell imager allows users to track dynamic cellular processes with high specificity by taking high-quality images to create real-time time-lapse movies.


Said Jan-Willem van Bree, CTO at CytoSMART Technologies, “Currently, fluorescent labeling is mostly used as an end-point measurement. However, time-lapse imaging of live cells can give much more information about biological processes. By using automated imaging at regular time intervals, the temporal resolution of the fluorescent data is increased, leading to even more relevant data about the cellular processes.

In this way, researchers can not only determine if a certain process has occurred, but also when it occurred and at what speed. Our customers have been asking us to develop a small and easy-to-use microscope with integrated image analysis of bright-field and fluorescence data. We have listened and made it happen.”

The main features and benefits of the CytoSMART Lux3 FL include:

  • Integrated image analysis of bright-field and fluorescence area or fluorescence object count.
  • Time-lapse movies to investigate the development of cellular processes.
  • Expanded number of variables researchers can analyze in their cell culture using green and red fluorescence.
  • Remote data accessibility via the CytoSMART Cloud with a smartphone, tablet, or laptop outside the lab.
  • Portable, easy-to-use, and incubator friendly live-cell imager.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy